Aclipse Therapeutics

Executive Summary

Aclipse Therapeutics is a privately held, Phase 2-stage biotechnology company based in Durham, NC, focused on developing novel small molecule therapeutics for severe, life-threatening neuromuscular diseases. The company leverages genomic, proteomic, and biomarker data to create disease-modifying drug candidates that target molecular pathways regulating inflammation, cellular stress, and protein misfolding. Founded in 2018, Aclipse aims to address high unmet needs in neuromuscular disorders where few effective treatments exist. The company's lead program is advancing through Phase 2 clinical trials, with initial efficacy and biomarker data expected to read out in the second half of 2026. Aclipse has also been active in securing intellectual property and exploring strategic partnerships to support its pipeline. With a strong scientific foundation and a focus on validated pathways, Aclipse represents a compelling investment opportunity in the neuromuscular space, though it remains pre-revenue and dependent on successful trial outcomes and financing.

Upcoming Catalysts (preview)

• H2 2026Phase 2 Clinical Trial Data Readout for Lead Candidate40% success
• 2026Series B Financing or Strategic Partnership60% success
• 2026FDA Orphan Drug Designation for Lead Program70% success